IMPACT BIOMEDICAL INC.
IBONext catalyst
IMP9064
Solid Tumor
Get an email about IBO's next catalysts
Track IMPACT BIOMEDICAL (IBO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 2 past
IMP9064 Phase 2 Est. Readout
Estimated primary completion for IMP9064 trial (NCT05269316) in Solid Tumor. Topline data typically follows completion by weeks to months.
SourceSenaparib Phase 2 Est. Readout
Estimated primary completion for Senaparib trial (NCT06617923) in Ovary Cancer. Topline data typically follows completion by weeks to months.
SourceHow IBO's past catalysts played out
Market Overview
Stock performance and key metrics
IMP4927
Ovarian Cancer
Senaparib
Ovary Cancer
IMP4297
Ovarian Cancer
IMP9064
Solid Tumor
IMP4297(senaparib)
Advanced Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMP4927 | Phase 3 | Ovarian Cancer | - | - |
Senaparib | Phase 2 | Ovary Cancer | - | - |
IMP4297 | Phase 2 | Ovarian Cancer | - | - |
IMP9064 | Phase 2 | Solid Tumor | - | - |
IMP4297(senaparib) | Phase 2 | Advanced Solid Tumours | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in IMPACT BIOMEDICAL INC.'s drug pipeline?β
CatalystAlert tracks 5 drug candidates in IMPACT BIOMEDICAL INC.'s (IBO) pipeline across Phase 3, Phase 2. Its lead program is IMP4927 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IMPACT BIOMEDICAL INC.'s next FDA catalyst?β
IMPACT BIOMEDICAL INC.'s (IBO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IBO biotech catalysts?β
Add IBO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IMPACT BIOMEDICAL INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
